Adoptive cell therapy with a nonmyeloablative preparative regimen using either tumor-infiltrating lymphocytes or T-cell receptor-transduced cells, combined with IL-2, can mediate a complete and durable regression of melanoma brain metastases in patients [115]. This evidence concerns the gene IL2 and melanoma.